PMID- 30672141
OWN - NLM
STAT- MEDLINE
DCOM- 20200227
LR  - 20200309
IS  - 1099-0496 (Electronic)
IS  - 8755-6863 (Print)
IS  - 1099-0496 (Linking)
VI  - 54
IP  - 5
DP  - 2019 May
TI  - Pulmonary findings in infants with cystic fibrosis during the first year of life: 
      Results from the Baby Observational and Nutrition Study (BONUS) cohort study.
PG  - 581-586
LID - 10.1002/ppul.24261 [doi]
AB  - IMPORTANCE: Treatment recommendations for infants with CF standardize care, but 
      most surveillance or treatment guidance of pulmonary manifestations are 
      consensus-based due to sparse evidence. OBJECTIVE: To report observations about 
      pulmonary correlates of growth and other clinical features in infants with CF. 
      METHODS: We analyzed data from the prospective Baby Observational and Nutrition 
      Study conducted in 28 centers across the US, including clinical features, 
      medications, guardian diaries of respiratory symptoms, oropharyngeal swab 
      cultures and chest radiographs (CXR) collected over the first year of life. 
      RESULTS: Cough was reported in 84% of infants in the first year. Up to 30% had 
      clinically important cough but only 6.3% had crackles; 16.5% had wheeze. 
      Wisconsin CXR score was above 5 in 23% (normal = 0; maximum score = 100). 
      Pseudomonas was recovered from at least one respiratory culture in 24% of infants 
      and was associated with crackles/wheezes and use of proton pump inhibitors (PPI) 
      (OR = 5.47; 95%CI = 1.36, 21.92; P = 0.02) or PPI plus histamine-2 (H2) blocker 
      (OR = 8.2; 95%CI = 2.41, 27.93; P = 0.001), but not H2 blocker alone. 
      Hospitalization for respiratory indications occurred in 18% of infants and was 
      associated with crackles/wheeze and abnormal CXR but not low weight, Pseudomonas 
      or use of acid blockade. CONCLUSIONS: Cough is common in infants with CF, but few 
      present with crackles/wheeze or CXR changes. Pseudomonas is associated with use 
      of PPI or PPI plus H2 blocker, but not with respiratory hospitalization. These 
      observations cannot prove cause and effect but add to our understanding of 
      pulmonary manifestations of CF in infants. TRIAL REGISTRATION: United States 
      ClinicalTrials.Gov registry NCT01424696 (clinicaltrials.gov).
CI  - (c) 2019 Wiley Periodicals, Inc.
FAU - Goetz, Danielle
AU  - Goetz D
AUID- ORCID: 0000-0001-5467-5423
AD  - Department of Pediatrics, Division of Pediatric Pulmonology, University at 
      Buffalo, Buffalo, New York.
FAU - Kopp, Benjamin T
AU  - Kopp BT
AUID- ORCID: 0000-0002-2021-7990
AD  - Nationwide Children's Hospital, Division of Pulmonary Medicine, Columbus, Ohio.
FAU - Salvator, Ann
AU  - Salvator A
AD  - Biostatistics Core, Research Institute at Nationwide Children's Hospital, 
      Columbus, Ohio.
FAU - Moore-Clingenpeel, Melissa
AU  - Moore-Clingenpeel M
AD  - Biostatistics Core, Research Institute at Nationwide Children's Hospital, 
      Columbus, Ohio.
FAU - McCoy, Karen
AU  - McCoy K
AD  - Nationwide Children's Hospital, Division of Pulmonary Medicine, Columbus, Ohio.
FAU - Leung, Daniel H
AU  - Leung DH
AD  - Baylor College of Medicine, Department of Pediatrics, Division of 
      Gastroenterology, Hepatology, and Nutrition, Houston, Texas.
FAU - Kloster, Margaret
AU  - Kloster M
AD  - Cystic Fibrosis Foundation Therapeutics Development Network Coordinating Center, 
      Seattle Children's Research Institute, Seattle, Washington.
AD  - Department of Pediatrics, Division of Pulmonary and Sleep Medicine, University of 
      Washington, Seattle, Washington.
FAU - Ramsey, Bonnie R
AU  - Ramsey BR
AD  - Cystic Fibrosis Foundation Therapeutics Development Network Coordinating Center, 
      Seattle Children's Research Institute, Seattle, Washington.
AD  - Department of Pediatrics, Division of Pulmonary and Sleep Medicine, University of 
      Washington, Seattle, Washington.
FAU - Heltshe, Sonya H
AU  - Heltshe SH
AD  - Cystic Fibrosis Foundation Therapeutics Development Network Coordinating Center, 
      Seattle Children's Research Institute, Seattle, Washington.
AD  - Department of Pediatrics, Division of Pulmonary and Sleep Medicine, University of 
      Washington, Seattle, Washington.
FAU - Borowitz, Drucy
AU  - Borowitz D
AD  - Department of Pediatrics, Division of Pediatric Pulmonology, University at 
      Buffalo, Buffalo, New York.
AD  - Cystic Fibrosis Foundation, Bethesda, Maryland.
LA  - eng
SI  - ClinicalTrials.gov/NCT01424696
GR  - P30 DK089507/DK/NIDDK NIH HHS/United States
GR  - R01 DK095738/DK/NIDDK NIH HHS/United States
GR  - RO1DK095738/NH/NIH HHS/United States
PT  - Journal Article
PT  - Observational Study
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20190122
PL  - United States
TA  - Pediatr Pulmonol
JT  - Pediatric pulmonology
JID - 8510590
RN  - 0 (Histamine H2 Antagonists)
RN  - 0 (Proton Pump Inhibitors)
SB  - IM
MH  - Cohort Studies
MH  - Cough/epidemiology
MH  - Cystic Fibrosis/diagnostic imaging/epidemiology/*physiopathology
MH  - Female
MH  - Histamine H2 Antagonists/therapeutic use
MH  - Hospitalization/statistics & numerical data
MH  - Humans
MH  - Infant
MH  - Lung/diagnostic imaging/physiopathology
MH  - Male
MH  - Nutritional Status
MH  - Prospective Studies
MH  - Proton Pump Inhibitors/therapeutic use
MH  - Pseudomonas Infections/epidemiology
MH  - Respiratory Sounds
MH  - Respiratory Tract Infections/epidemiology
MH  - United States/epidemiology
PMC - PMC6557408
MID - NIHMS1033007
OTO - NOTNLM
OT  - CF
OT  - cystic fibrosis
OT  - nutrition
OT  - pulmonary outcomes
EDAT- 2019/01/24 06:00
MHDA- 2020/02/28 06:00
PMCR- 2019/06/10
CRDT- 2019/01/24 06:00
PHST- 2018/09/04 00:00 [received]
PHST- 2018/12/30 00:00 [accepted]
PHST- 2019/01/24 06:00 [pubmed]
PHST- 2020/02/28 06:00 [medline]
PHST- 2019/01/24 06:00 [entrez]
PHST- 2019/06/10 00:00 [pmc-release]
AID - 10.1002/ppul.24261 [doi]
PST - ppublish
SO  - Pediatr Pulmonol. 2019 May;54(5):581-586. doi: 10.1002/ppul.24261. Epub 2019 Jan 
      22.